Alpsoy E, Yilmaz E, Basaran E
Department of Dermatology, Akdeniz University Medical Faculty, Antalya, Turkey.
J Dermatol. 1996 Apr;23(4):259-62. doi: 10.1111/j.1346-8138.1996.tb04009.x.
Terbinafine, an orally active antifungal agent of the allylamine class, is effective in the treatment of dermatophyte onycomycosis. Its pharmacologic and pharmacokinetic properties give strong support to the possibility that intermittent treatment courses may be equally effective in onychomycosis in general. The present randomized and controlled study was carried out to determine whether intermittent therapy with terbinafine was effective in dermatophyte toe-onychomycosis. Sixty patients with mycologically proven toenail dermatophyte onychomycosis were included in the study. Patients were equally allocated to treatment groups in a random manner. Group 1 was given 250 mg/day of terbinafine for 3 months. Group 2 was given 500 mg/day of terbinafine for 7 days during the first week of each month for 3 months. Nails were examined clinically and mycologically at monthly intervals. All patients were followed up for 48 weeks after starting the treatment. Of the patients who entered the study, 24 in Group I and 23 in Group 2 were evaluable for efficacy. At the end of the follow-up period, the cure rate (negative microscopy and culture) was 79.2% in Group 1 and 73.9% in Group 2; this difference was not significant (p: 0.79). The results indicate that intermittent therapy with terbinafine is as effective as 3-month treatment in dermatophyte toe-onychomycosis.
特比萘芬是一种口服有效的烯丙胺类抗真菌药物,对皮肤癣菌性甲真菌病的治疗有效。其药理和药代动力学特性有力地支持了这样一种可能性,即间歇性治疗疗程总体上在甲真菌病中可能同样有效。本随机对照研究旨在确定特比萘芬间歇性治疗对皮肤癣菌性趾甲甲真菌病是否有效。60例经真菌学证实的趾甲皮肤癣菌性甲真菌病患者纳入本研究。患者被随机平均分配到各治疗组。第1组给予特比萘芬250mg/天,持续3个月。第2组在每个月的第一周给予特比萘芬500mg/天,共7天,持续3个月。每月对指甲进行临床和真菌学检查。所有患者在开始治疗后随访48周。进入本研究的患者中,第1组有24例、第2组有23例可进行疗效评估。随访期末,第1组的治愈率(显微镜检查和培养阴性)为79.2%,第2组为73.9%;差异无统计学意义(p:0.79)。结果表明,特比萘芬间歇性治疗在皮肤癣菌性趾甲甲真菌病中的疗效与3个月治疗相当。